Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,686 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $22,696.70. Following the transaction, the insider directly owned 420,047 shares in the company, valued at $3,549,397.15. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Relay Therapeutics Stock Up 0.8%

RLAY stock traded up $0.06 during mid-day trading on Thursday, reaching $7.71. 1,788,553 shares of the company traded hands, compared to its average volume of 2,246,533. The firm’s 50 day moving average price is $7.93 and its 200 day moving average price is $5.93. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -4.41 and a beta of 1.55. Relay Therapeutics, Inc. has a fifty-two week low of $1.77 and a fifty-two week high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). On average, analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Trading of Relay Therapeutics

Several large investors have recently bought and sold shares of the company. Commodore Capital LP boosted its holdings in Relay Therapeutics by 27.3% in the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after purchasing an additional 3,650,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after purchasing an additional 295,701 shares in the last quarter. Bellevue Group AG raised its holdings in Relay Therapeutics by 1.4% during the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after acquiring an additional 114,740 shares during the period. Geode Capital Management LLC boosted its stake in Relay Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock worth $11,176,000 after purchasing an additional 159,548 shares during the period. Finally, Millennium Management LLC raised its position in shares of Relay Therapeutics by 14.6% during the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock valued at $7,710,000 after buying an additional 374,491 shares during the last quarter. 96.98% of the stock is owned by institutional investors.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Neutral Sentiment: AAII published an explainer on why RLAY slid ~5.18%, summarizing market reaction and citing recent insider transactions as a driver. AAII Article
• Negative Sentiment: CFO Thomas Catinazzo sold 15,515 shares across Jan. 27–28 (13,820 shares at $7.62 and 1,695 at $8.45), totaling roughly $119k + $14k ? $120k in disclosed sales; ownership fell ~5.22% then 0.68%. SEC filing: Catinazzo SEC Filing
• Negative Sentiment: Insider Peter Rahmer sold 13,038 shares across Jan. 27–28 (11,684 at $7.62 and 1,354 at $8.45), about $89k + $11.4k ? $100k in sales; his holding decreased ~4.03% then 0.49%. SEC filing: Rahmer SEC Filing
• Negative Sentiment: Insider Donald A. Bergstrom sold 21,581 shares across Jan. 27–28 (18,895 at $7.62 and 2,686 at $8.45), about $144k + $22.7k ? $167k in sales; his stake fell ~4.28% then 0.64%. SEC filing: Bergstrom SEC Filing

Analyst Upgrades and Downgrades

RLAY has been the topic of several research reports. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $13.00 in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Finally, Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.